Drug Profile
Loxoprofen - Daiichi Sankyo Company
Alternative Names: CS-600G; Loxonin; Loxonin Pap; Loxonin Tape; Loxoprofen gel; Loxoprofen poultice; Loxoprofen sodium; Loxoprofen tape; LX-A; LX-PLatest Information Update: 04 Jan 2024
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer Cardinal Health; Daiichi Sankyo Brasil; Daiichi Sankyo Company; Lead Chemical
- Class Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pain
Most Recent Events
- 04 Jan 2024 Discontinued - Phase-III for Pain in Brazil (Transdermal)
- 12 Aug 2023 Lead Chemical completes the phase III trial in Pain (In adolescents, In adults) in Germany (Transdermal) (EudraCT2020-003543-29)
- 24 Mar 2021 Phase-III clinical trials in Pain (In adolescents, In adults) in Germany (Transdermal) before March 2021 (EudraCT2020-003543-29)